lesinurad 200 MG
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Background Lesinurad (LESU) is a selective uric acid reabsorption inhibitor approved in the United States and European Union at a…
Background Three randomized, double-blind, Phase III trials reported that greater proportions of patients treated with lesinurad…
Background Two replicate, randomized, core Phase III trials (CLEAR 1 and 2) reported significantly more subjects treated with…